Akèy › Limfòm Burkitt › Main
Etid klinik pou Limfòm Burkitt nan Main
4 etid pou Limfòm Burkitt ap chèche patisipan nan sit nan Main.
Vil nan Main
Tèks ofisyèl etid la (Anglè)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Maine Children's Cancer Program, Scarborough
Ap rekriteFaz 2
366 Days – 46 Years · Tout sèks · Mizajou Oct 2, 2026 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Maine Children's Cancer Program, Scarborough
Ap rekriteFaz 2
365 Days · Tout sèks · Mizajou Sep 25, 2026 · NCT06317662A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Eastern Maine Medical Center, Bangor
- Maine Children's Cancer Program, Scarborough
Ap rekriteFaz 2
Laj 1 a 30 · Tout sèks · Mizajou Sep 1, 2026 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Eastern Maine Medical Center, Bangor
- Maine Children's Cancer Program, Scarborough
Ap rekriteFaz 3
365 Days – 25 Years · Tout sèks · Mizajou Aug 25, 2026 · NCT03959085Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.